超越化疗:网络元分析揭示了针对光线乳腺癌的最佳新辅助策略
Xinyu Li1, Peijing Du2, Tao Huang1
1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer medicine
|February 13, 2026
概括
新辅助内分泌疗法 (NET) 是HR+/HER2-乳腺癌化疗的安全替代方案. CDK4/6抑制剂加上内分泌疗法 (ET) 显示出优异的瘤减少和安全性,支持术后治疗的缓解.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 临床试验 临床试验
背景情况:
- 激素受体阳性 (HR+),HER2阴性 (HER2-) 乳腺癌是最常见的亚型.
- 新辅助性内分泌疗法 (NET) 的疗效与新辅助性化疗 (NCT) 的疗效相当,对这一患者群体的毒性降低.
- 这项研究重点关注局部晚期或不可手术的HR+/HER2-乳腺癌.
研究的目的:
- 对HR+/HER2-乳腺癌的新辅助疗法进行系统审查和网络元分析.
- 为指导新辅助治疗策略的临床决策.
- 为了比较不同新辅助剂方案的疗效和安全性.
主要方法:
- 对HR+/HER2-乳腺癌的II/III期新辅助药临床试验的分析.
- 主要终点包括通过触摸和成像的整体响应率 (ORR).
- 二级终点评估了乳腺保护手术 (BCS) 率,病理完整反应 (pCR) 和安全性,有效性由SUCRA排名.
主要成果:
- CDK4/6抑制剂+ET组合疗法显示了最高的ORR通过触摸 (90.9%) 和BCS率 (77.1%).
- 化疗在放射学上获得了最高的ORR (87.6%),而TKI + ET在PCR (79.6%) 中领先.
- 选择性雌激素受体降解剂表现出最佳耐受性,完成率高 (84.1%),严重不良事件最小 (90.4%).
结论:
- 新辅助内分泌疗法 (NET) 是针对HR+/HER2-乳腺癌的新辅助化疗 (NCT) 的可行替代方案.
- CDK4/6抑制剂+ET组合疗法提供优越的瘤减少和安全性.
- 这些发现支持NET作为优化患者结果和最大限度地减少治疗毒性的战略选择.
相关概念视频
Protein Networks
4.6K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.6K
Protein Networks
2.9K
2.9K
Cancer Survival Analysis
774
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
774
Directing Effect of Substituents: meta-Directing Groups
6.1K
Substituents on the benzene ring that direct an incoming electrophile to undergo substitution at the meta position are called meta directors. All meta directors either have a positive charge on the atom directly bonded to the ring or a partial positive charge. These groups function by withdrawing electrons from the ring through inductive and resonance effects. Consider the carbocation intermediates formed upon the addition of an electrophile on nitrobenzene at the...
6.1K
Network Covalent Solids
16.2K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
800
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
800


